

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

1. (Currently Amended) A peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 21 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:21, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is optionally formylated.

2. (Currently Amended) The peptide consisting of SEQ ID NO: 1 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:1 according to claim 1, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is optionally formylated.

3. (Currently Amended) ~~The~~ A peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 16 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:16 ~~according to claim 1~~, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is formylated.

4. (Currently Amended) ~~The~~ A peptide consisting of the amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 22 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 ~~according to claim 1~~, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is formylated.

5. (Currently Amended) ~~The~~ A peptide consisting of the amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 22 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 ~~according to claim 1~~, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal

transduction activity, and a methionine residue at the N-terminus, if any, is formylated and an isoleucine residue at the C-terminus, if any, is modified.

6. (Currently Amended) A peptide consisting of the amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 23 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:17 or SEQ ID NO:23, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is optionally formylated.

7. (Currently Amended) The peptide consisting of the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:17 according to claim 6, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is optionally formylated.

8. (Currently Amended) ~~The~~ A peptide consisting of the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 or SEQ ID NO: 20 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20 ~~according to claim 6~~, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is formylated.

9. (Currently Amended) ~~The~~ A peptide consisting of the amino acid sequence of SEQ ID NO: 23 or SEQ ID NO: 24 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24 ~~according to claim 6~~, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is formylated.

10. (Original) A medicament comprising the peptide, its amide or ester, or salts thereof, according to claim 1.

11. (Original) A medicament comprising the peptide, its amide or ester, or salts thereof, according to claim 6.

12. (Currently amended) The medicament according to any one of claims 10 or claim 11 and 65, which is a cell migration irritant.

13. (Currently amended) The medicament according to any one of claims 10 or claim 11 and 65, which is an anti-inflammatory agent.

14. (Currently Amended) The medicament according to any one of claims 10 or claim 11 and 65, which is a prophylactic/therapeutic agent for asthma, allergic disease, inflammation, ocular infection, lupus erythematosus, psoriasis, rheumatoid osteoarthritis, synovitis, cerebral infarction, edema, multiple sclerosis, Alzheimer's Disease, AIDS, diabetes mellitus, ulcerative colitis, pneumonia, arteriosclerosis, viral infection, myocardial infarction, or immunodeficiency~~asthma, allergosis, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, brain hemorrhage, brain infarction, head injury, cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), encephalopathy associated with AIDS, cerebral meningitis, diabetes mellitus, arthritis rheumatoides, osteoarthritis, rheumatoid spondylitis, gouty arthritis, synovial inflammation, blood poisoning, Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, lung tuberculosis, cachexia, arterial sclerosis, Creutzfeldt-Jakob disease, viral infection, angina cordis, cardiac infarction, congestive failure, hepatitis, exaggerated immune response after medical transplantation, dialysis hypotension, diffuse intravascular coagulation syndrome, or immunodeficiency.~~

15. (Previously presented) An isolated antibody against the peptide, its amide or ester, or salts thereof, according to claim 1.

16. (Previously presented) An isolated antibody against the peptide, its amide or ester, or salts thereof, according to claim 6.

17. (Original) A diagnostic agent comprising the antibody according to claim 15.

18. (Original) A diagnostic agent comprising the antibody according to claim 16.

19. (Currently Amended) The diagnostic agent according to any one of claims 17, or claim 18 and 67, which is a diagnostic agent for asthma, allergic disease, inflammation, ocular infection, lupus erythematosus, psoriasis, rheumatoid osteoarthritis, synovitis, cerebral infarction, edema, multiple sclerosis, Alzheimer's Disease, AIDS, diabetes mellitus, ulcerative colitis, pneumonia, arteriosclerosis, viral infection, myocardial infarction, or immunodeficiency~~asthma, allergosis, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, brain hemorrhage, brain infarction, head injury, cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), encephalopathy associated with AIDS, cerebral meningitis, diabetes mellitus, arthritis rheumatoides, osteoarthritis, rheumatoid spondylitis, gouty arthritis, synovial inflammation, blood poisoning, Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, lung tuberculosis, cachexia, arterial sclerosis, Creutzfeldt-Jakob disease, viral infection, angina cordis, cardiac infarction, congestive failure, hepatitis, exaggerated immune response after medical transplantation, dialysis hypotension, diffuse intravascular coagulation syndrome, or immunodeficiency.~~

20. (Previously presented) A medicament comprising the isolated antibody according to claim 15.

21. (Previously presented) A medicament comprising the isolated antibody according to claim 16.

22. (Currently amended) The medicament according to any one of claims 20 or claim 21 and 68, which is a cell migration depressant.

23. (Currently amended) The medicament according to any one of claims 20 or claim 21 and 68, which is a prophylactic/therapeutic agent for infectious disease.

24. (Currently Amended) A method for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G protein-coupled receptor protein or salts thereof, and the peptide according to claim 1, its amide or ester, or salts thereof, which comprises;

using (A)

(a) contacting (1) the receptor protein comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity, and with (2) (i) the peptide according to claim 1, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 1, its amide or ester, or salts thereof,

and

(b) measuring a binding level of 2(i) said peptide, its amide or ester, or salts thereof, to (1) said receptor protein;

(B)

(a) contacting (1) the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2. a partial peptide of the receptor protein or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity and a test compound, with 2(i) the peptide according to claim 1, its amide or ester or salts thereof, or (ii) the compound or a salt thereof, that alters a binding property between the

receptor protein or a salt thereof, and the peptide according to claim 1, its amide or ester, or salts thereof, to (1) said receptor protein; and
(C) comparing the binding level of step (A) with the binding level of step (B).

25. (Currently Amended) A method for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G protein-coupled receptor protein or salts thereof, and the peptide according to claim 6, its amide or ester, or salts thereof, which comprises;

(A)

(a) contacting using (1) the receptor protein comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and with (2) (i) the peptide according to claim 6, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 6, its amide or ester, or salts thereof,

and

(b) measuring a binding level of (2)(i) said peptide, its amide or ester, or salts thereof, to (1) said receptor protein;

(B)

(a) contacting (1) the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity and a test compound, with (2)(i) the peptide according to claim 6, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof, that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 6, its amide or ester, or salts thereof,

and

(b) measuring a binding level of (2) (i) said peptide, its amide or ester, or salts thereof, to (1) said protein receptor; and

(C) comparing the binding level of step (A) with the binding level of step (B).

26. (Currently amended) The screening method according to any one of claims 24, 25, 70, 71 and 72, 24 or claim 25, wherein the G protein-coupled receptor protein comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, is a G protein-coupled receptor protein consisting of the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6.

27. (Currently Amended) A kit for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G protein-coupled receptor protein or salts thereof, and the peptide according to claim 1, its amide or ester, or salts thereof, which comprises;

(A) using (1) the receptor protein comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity, or (2) a cell producing the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homolog to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity, and,

(B)(1)(2) (i) the peptide according to claim 1, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 1, its amide or ester, or salts thereof or (2) (i) a labeled peptide according to claim 1, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding

property between the receptor protein or a salt thereof, and a labeled peptide according to claim 1, its amide, or ester, or salts thereof.

28. (Currently Amended) A kit for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G protein-coupled receptor protein or salts thereof, and the peptide according to claim 6, its amide or ester, or salts thereof, which comprises;

(A) using (1) the receptor protein comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity, or (2) a cell producing the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity, and,

(B)(1)(2) (i) the peptide according to claim 6, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 6, its amide or ester, or salts thereof, or (2) (i) a labeled peptide according to claim 6, its amide or ester or salts thereof, or (ii) the compound or salt thereof that alters a binding property between the receptor protein or a salt thereof, and a labeled peptide according to claim 6, its amide or ester, or salts thereof.

29-57. (canceled)

58. (Currently Amended) A method for stimulating a cell migration, or a method for preventing/treating Asthma, allergic disease, inflammation, ocular infection, lupus erythematosus, psoriasis, Rheumatoid osteoarthritis, synovitis, cerebral infarction, edema, multiple sclerosis, Alzheimer's disease, AIDS, diabetes mellitus, ulcerative colitis, pneumonia, arteriosclerosis, viral infection , myocardial infarction or

~~immunodeficiency, asthma, allergosis, inflammation, inflammatory eye diseases, Addison's disease, autoimmune hemolytic anemia, systemic lupus erythematosus, psoriasis, rheumatism, brain hemorrhage, brain infarction, head injury, cord injury, brain edema, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), encephalopathy associated with AIDS, cerebral meningitis, diabetes mellitus, arthritis rheumatoides, osteoarthritis, rheumatoid spondylitis, gouty arthritis, synovial inflammation, blood poisoning, Crohn's disease, ulcerative colitis, chronic pneumonia, pulmonary silicosis, pulmonary sarcoidosis, lung tuberculosis, cachexia, arterial sclerosis, Creutzfeldt Jakob disease, viral infection, angina cordis, cardiac infarction, congestive failure, hepatitis, exaggerated immune response after medical transplantation, dialysis hypotension, diffuse intravascular coagulation syndrome, or immunodeficiency, which comprises administering to a mammal an effective dose of (i) the peptide, its amide or ester, or salts thereof, according to claim 1, (ii) the peptide, its amide or ester, or salts thereof, according to claim 6, (iii) the peptide, its amide or ester, or salts thereof, according to claim 62 the G-protein-coupled receptor protein, its partial peptide, or salts thereof, according to claim 29, or (iv) the polynucleotide according to claim 31.~~

59. (Canceled)

60. (Currently amended) A method for inhibiting a cell stimulation, or a method for preventing/treating infectious disease, which comprises administering to a mammal an effective dose of (i) the antibody according to claim 15, (ii) the antibody according to claim 16, (iii) the antibody according to claim 6636, ~~or (iv) the polynucleotide according to claim 37.~~

61. (canceled)

62. (New) A peptide consisting of the amino acid sequence of SEQ ID NO:16 or SEQ ID NO:22 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:16 or SEQ ID NO:22, its amide or ester, or salts thereof,

wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is optionally formylated.

63. (New) The peptide consisting of the amino acid sequence of SEQ ID NO:16 or SEQ ID NO:22 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:16 or SEQ ID NO:22 according to claim 62, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or signal transduction activity, and a methionine residue at the N-terminus, if any, is formylated.

64. (New) The peptide consisting of the amino acid sequence of SE ID NO:16 or SEQ ID NO:22 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:16 or SEQ ID NO:22 according to claim 62, its amide or ester, or salts thereof, wherein the peptide has a ligand activity or a signal transduction activity, and a methionine residue at the N-terminus, if any, is formylated and an isoleucine residue at the C-terminus, if any, is modified.

65 (New) A medicament comprising the peptide, its amide or ester, or salts thereof, according to claim 62.

66. (New) An isolated antibody against the peptide, its amide or ester, or salts thereof, according to claim 62.

67. (New) A diagnostic agent comprising the antibody according to claim 66.

68. (New) A medicant comprising the isolated antibody according to claim 66.

69. (New) A method for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G-protein-coupled receptor protein or salts thereof, and the peptide according to claim 62, its amide or ester, or salts thereof, which comprises:

(A)

- (a) contacting (1) the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity, with (2) (i) the peptide according to claim 62, its amide or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 62, its amide or ester, or salts thereof,
and
- (b) measuring a binding level of (2) (i) said peptide, its amide or ester, or salts thereof, to (1) said receptor protein;
- (B)
 - (a) contacting (1) the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity and a test compound with (2) (i) the peptide according to claim 62, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 62, its amide or ester, or salts thereof,
and
 - (b) measuring a binding level of (2) (i) said peptide, its amide or ester, or salts thereof, to (1) said receptor protein; and
- (C) comparing the binding level of step (A) with the binding level of step (B).

70. (New) A method for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G protein-coupled receptor protein or salts thereof, and the peptide according to claim 2, its amide or ester, or salts thereof, which comprises:

(A)

(a) contacting (1) a cell producing the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or its salts thereof wherein the peptide has a ligand activity or a signal transduction activity, with (2)(i) the peptide according to claim 62, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 62, its amide or ester, or salts thereof,
and

(b) measuring a cell stimulating activity;

(B)

(a) contacting (1) a cell producing the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least a 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity and a test compound with (2)(i) the peptide according to claim 62, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 62, its amide or ester, or salts thereof,
and

(b) measuring a cell stimulating activity; and

(C) comparing the cell stimulating activity of step (A) with the cell stimulating activity of step (B).

71. (New) A method for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G protein-coupled receptor protein or salts thereof, and the peptide according to claim 1, its amide or ester, or salts thereof, which comprises:

(A)

(a) contacting (1) a cell producing the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or its salts thereof wherein the peptide has a ligand activity or a signal transduction activity, with (2)(i) the peptide according to claim 1, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 1, its amide or ester, or salts thereof,
and

(b) measuring a cell stimulating activity;

(B)

(a) contacting (1) a cell producing the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least a 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity and a test compound with (2)(i) the peptide according to claim 1, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 1, its amide or ester, or salts thereof,
and

(b) measuring a cell stimulating activity; and

(C) comparing the cell stimulating activity of step (A) with the cell stimulating activity of step (B).

72. (New) A method for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G protein-coupled receptor protein or salts thereof, and the peptide according to claim 6, its amide or ester, or salts thereof, which comprises:

(A)

(a) contacting (1) a cell producing the receptor protein comprising the amino acid of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity, with (2) (i) the peptide according to claim 6, its amide or ester, or salts thereof, or (ii) the compound or salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 6m its amide or ester, or salts thereof,
and

(b) measuring a cell stimulating activity;

(B)

(a) contacting (1) a cell producing the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity and a test compound, with (2) (i) the peptide according to claim 6, its amide or ester, or salts thereof, or (ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 6, its amide or ester, or salts thereof,
and

(b) measuring a cell stimulating activity; and

(C) comparing the cell stimulating activity of step (A) with the cell stimulating activity of step (B).

73. (New) A kit for screening a compound or a salt thereof that alters a binding property or a signal transduction between a G protein-coupled receptor protein or salts thereof, and the peptide according to claim 62, its amide or ester, or salts thereof, which comprises:

(A)

(1) the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity,
or

(2) a cell producing the receptor protein comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% homology to the amino acid sequence of SEQ ID NO:2, a partial peptide of the receptor protein or salts thereof wherein the peptide has a ligand activity or a signal transduction activity;

(B)

(1)

(i) the peptide according to claim 62, its amide or ester, or salts thereof,
or

(ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and the peptide according to claim 62, its amide or ester, or salts thereof,

or

(2)

(i) a labeled peptide according to claim 62, its amide or ester, or salts thereof,
or

(ii) the compound or a salt thereof that alters a binding property between the receptor protein or a salt thereof, and a labeled peptide according to claim 62, its amide or ester, or salts thereof.